[go: up one dir, main page]

GB0111146D0 - Methods - Google Patents

Methods

Info

Publication number
GB0111146D0
GB0111146D0 GBGB0111146.7A GB0111146A GB0111146D0 GB 0111146 D0 GB0111146 D0 GB 0111146D0 GB 0111146 A GB0111146 A GB 0111146A GB 0111146 D0 GB0111146 D0 GB 0111146D0
Authority
GB
United Kingdom
Prior art keywords
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0111146.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Priority to GBGB0111146.7A priority Critical patent/GB0111146D0/en
Publication of GB0111146D0 publication Critical patent/GB0111146D0/en
Priority to EP02720315A priority patent/EP1418938A1/en
Priority to PCT/GB2002/002087 priority patent/WO2002089834A1/en
Priority to CA002483658A priority patent/CA2483658A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0111146.7A 2001-05-04 2001-05-04 Methods Ceased GB0111146D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GBGB0111146.7A GB0111146D0 (en) 2001-05-04 2001-05-04 Methods
EP02720315A EP1418938A1 (en) 2001-05-04 2002-05-07 Bont/e or snap-25e for treating botulinum toxin a or c1 poisoning and inhibiting muscle contraction
PCT/GB2002/002087 WO2002089834A1 (en) 2001-05-04 2002-05-07 Bont/e or snap-25e for treating botulinum toxin a or c1 poisoning and inhibiting muscle contraction
CA002483658A CA2483658A1 (en) 2001-05-04 2002-05-07 Bont/e or snap-25e for treating botulinum toxin a or c1 poisoning and inhibiting muscle contraction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0111146.7A GB0111146D0 (en) 2001-05-04 2001-05-04 Methods

Publications (1)

Publication Number Publication Date
GB0111146D0 true GB0111146D0 (en) 2001-06-27

Family

ID=9914167

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0111146.7A Ceased GB0111146D0 (en) 2001-05-04 2001-05-04 Methods

Country Status (4)

Country Link
EP (1) EP1418938A1 (en)
CA (1) CA2483658A1 (en)
GB (1) GB0111146D0 (en)
WO (1) WO2002089834A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2857098B1 (en) * 2003-07-04 2006-05-05 Inst Nat Sante Rech Med METHOD FOR THE EVIDENCE OF A MOLECULAR EVENT IN A CELL USING FLUORESCENT MARKER PROTEINS
US7172764B2 (en) 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
EP1761558A1 (en) 2004-06-30 2007-03-14 Allergan, Inc. Optimizing expression of active botulinum toxin type e
ES2356883B1 (en) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. COMPOSITION FOR THE TREATMENT OF PAIN AND / OR INFLAMMATION.
EP2337790B1 (en) * 2008-08-29 2016-07-13 Merz Pharma GmbH & Co. KGaA Clostridial neurotoxins with altered persistency
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
JP7604222B2 (en) * 2017-03-22 2024-12-23 ボンチ インコーポレイテッド Therapeutic Botulinum Neurotoxins
AU2018237205A1 (en) * 2017-03-22 2019-10-31 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
US20230405098A1 (en) * 2022-06-16 2023-12-21 Innomed Technologies, Inc. Type e botulinum toxin to treat botulism

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69427869T2 (en) * 1993-12-28 2002-04-11 Allergan Sales Inc BOTULINUMTOXINS FOR TREATING HYPERHYDROSIS
US6169074B1 (en) * 1996-03-18 2001-01-02 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
US6214602B1 (en) * 1998-08-28 2001-04-10 Promega Corporation Host cells for expression of clostridial toxins and proteins
CA2379532A1 (en) * 1999-08-20 2001-03-15 Imperial College Innovations Limited Isoforms of snare molecules and the uses thereof in modulation of cellular exocytosis
CA2380457A1 (en) * 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins

Also Published As

Publication number Publication date
EP1418938A1 (en) 2004-05-19
CA2483658A1 (en) 2002-11-14
WO2002089834A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
DE50202633D1 (en) Ophthalmoskop
GB0108968D0 (en) Methods
GB0104948D0 (en) Novel methods
GB0120042D0 (en) Methods
GB0126251D0 (en) Methods
GB0111146D0 (en) Methods
GB0116249D0 (en) Methods
DE50214962D1 (en) Heterocyclylarylsulfonamide
GB0124577D0 (en) Novel methods
DE60236364D1 (en) Hepatitis-c-virus-impfstoff
AU2002313943A8 (en) Electromobile
GB0118549D0 (en) Methods
GB0102393D0 (en) Cup-carrier
GB0118611D0 (en) Methods
GB0116076D0 (en) Methods
GB0112256D0 (en) Methods
GB0122697D0 (en) Methods
GB0123962D0 (en) Methods
GB0119344D0 (en) Methods
GB0127625D0 (en) Methods
GB0100941D0 (en) Methods
GB0114421D0 (en) Methods
GB0111639D0 (en) Methods
GB0111637D0 (en) Methods
GB0108227D0 (en) Methods

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)